156 related articles for article (PubMed ID: 9493588)
21. The effect of albumin priming solution on platelet activation during experimental long-term perfusion.
Adrian K; Mellgren K; Skogby M; Friberg LG; Mellgren G; Wadenvik H
Perfusion; 1998 May; 13(3):187-91. PubMed ID: 9638716
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacological studies of FUT-175, nafamstat mesilate. IV. Effects on coagulation, platelets and fibrinolysis].
Koshiyama Y; Ozeki M; Motoyoshi A; Fujita M; Iwaki M; Aoyama T
Nihon Yakurigaku Zasshi; 1984 Nov; 84(5):417-28. PubMed ID: 6519580
[TBL] [Abstract][Full Text] [Related]
23. Iloprost reduces procoagulant activity in the extracorporeal circuit.
Korn RL; Fisher CA; Stenach N; Jeevanandam V; Addonizio VP
J Surg Res; 1993 Oct; 55(4):433-40. PubMed ID: 7692141
[TBL] [Abstract][Full Text] [Related]
24. Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling conditions using vacuum tube samples from healthy volunteers.
Omote M; Asakura H; Takamichi S; Shibayama M; Yoshida T; Kadohira Y; Maekawa M; Yamazaki M; Morishita E; Nakao S; Wada T
Thromb Res; 2008; 123(2):390-5. PubMed ID: 18579183
[TBL] [Abstract][Full Text] [Related]
25. Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection.
Shimada M; Matsumata T; Shirabe K; Kamakura T; Taketomi A; Sugimachi K
J Am Coll Surg; 1994 May; 178(5):498-502. PubMed ID: 8167888
[TBL] [Abstract][Full Text] [Related]
26. Hemostasis during normal pregnancy and puerperium.
Hellgren M
Semin Thromb Hemost; 2003 Apr; 29(2):125-30. PubMed ID: 12709915
[TBL] [Abstract][Full Text] [Related]
27. Effects on blood compatibility in vitro by combining a direct P2Y12 receptor inhibitor and heparin coating of stents.
Christensen K; Larsson R; Emanuelsson H; Elgue G; Larsson A
Platelets; 2006 Aug; 17(5):318-27. PubMed ID: 16928604
[TBL] [Abstract][Full Text] [Related]
28. [The effects of FUT-175 (nafamostat mesilate) on blood coagulation and experimental disseminated intravascular coagulation (DIC)].
Koshiyama Y; Kobori A; Ogihara M; Yokomoto Y; Ohtani K; Shimamura K; Iwaki M
Nihon Yakurigaku Zasshi; 1987 Dec; 90(6):313-20. PubMed ID: 3443413
[TBL] [Abstract][Full Text] [Related]
29. [Changes in coagulation, fibrinolysis and platelet functions during extracorporeal circulation].
Kaizu K; Uriu K; Ikeda M
Nihon Rinsho; 2004 May; 62 Suppl 5():46-9. PubMed ID: 15197886
[No Abstract] [Full Text] [Related]
30. Recombinant Kunitz protease inhibitory domain of the amyloid beta-protein precursor as an anticoagulant in venovenous extracorporeal circulation in rabbits.
Annich G; White T; Damm D; Zhao Y; Mahdi F; Meinhardt J; Rebello S; Lucchesi B; Bartlett RH; Schmaier AH
Thromb Haemost; 1999 Nov; 82(5):1474-81. PubMed ID: 10595641
[TBL] [Abstract][Full Text] [Related]
31. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
[TBL] [Abstract][Full Text] [Related]
32. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
[TBL] [Abstract][Full Text] [Related]
33. Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma.
Chen CL; Wang SD; Zeng ZY; Lin KJ; Kao ST; Tani T; Yu CK; Wang JY
J Allergy Clin Immunol; 2006 Jul; 118(1):105-12. PubMed ID: 16815145
[TBL] [Abstract][Full Text] [Related]
34. Safety of recombinant human factor XIII in a cynomolgus monkey model of extracorporeal blood circulation.
Ponce R; Armstrong K; Andrews K; Hensler J; Waggie K; Heffernan J; Reynolds T; Rogge M
Toxicol Pathol; 2005; 33(6):702-10. PubMed ID: 16243775
[TBL] [Abstract][Full Text] [Related]
35. Nitric oxide in the oxygenator sweep gas reduces platelet activation during experimental perfusion.
Mellgren K; Friberg LG; Mellgren G; Hedner T; Wennmalm A; Wadenvik H
Ann Thorac Surg; 1996 Apr; 61(4):1194-8. PubMed ID: 8607682
[TBL] [Abstract][Full Text] [Related]
36. Thrombogenesis in sickle cell disease.
Tomer A; Harker LA; Kasey S; Eckman JR
J Lab Clin Med; 2001 Jun; 137(6):398-407. PubMed ID: 11385360
[TBL] [Abstract][Full Text] [Related]
37. [The effects of various anticoagulants on blood coagulation: with special reference to false positive lupus anticoagulants].
Onda H; Watanabe H
Rinsho Byori; 1989 Dec; 37(12):1385-91. PubMed ID: 2515325
[TBL] [Abstract][Full Text] [Related]
38. The effect of surface roughness on activation of the coagulation system and platelet adhesion in rotary blood pumps.
Linneweber J; Dohmen PM; Kertzscher U; Affeld K; Nosé Y; Konertz W
Artif Organs; 2007 May; 31(5):345-51. PubMed ID: 17470203
[TBL] [Abstract][Full Text] [Related]
39. Gabexate mesilate (Foy) as an anticoagulant in extracorporeal circulation in dogs and sheep.
Oedekoven B; Bey R; Mottaghy K; Schmid-Schönbein H
Thromb Haemost; 1984 Dec; 52(3):329-32. PubMed ID: 6442472
[TBL] [Abstract][Full Text] [Related]
40. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
Mousa SA
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):55-60. PubMed ID: 17179828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
